Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
NCT ID: NCT00365287
Last Updated: 2017-11-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
148 participants
Study Classification
INTERVENTIONAL
Study Start Date
2000-06-30
Study Completion Date
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil after transplant may stop this from happening.
PURPOSE: This phase I/II trial is studying the side effects of giving combination chemotherapy together with total-body irradiation before donor umbilical cord blood transplant and to see how well they work in treating patients with advanced hematologic cancer, metastatic breast cancer, or kidney cancer.
PURPOSE: This phase I/II trial is studying the side effects of giving combination chemotherapy together with total-body irradiation before donor umbilical cord blood transplant and to see how well they work in treating patients with advanced hematologic cancer, metastatic breast cancer, or kidney cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES:
Primary
* Determine the safety of nonmyeloablative preparative regimen comprising cyclophosphamide, fludarabine, and total-body irradiation with or without anti-thymocyte globulin, in terms of non-relapse mortality at day 100 post-transplantation, in patients with advanced hematologic malignancies, metastatic breast cancer, or renal cell cancer who are undergoing umbilical cord blood transplantation from an unrelated donor.
Secondary
* Determine the hematopoietic recovery and degree of chimerism on days 21, 60, 100, 180, and 360 post-transplantation.
* Determine the incidence of grade II-IV and III-IV acute graft-versus-host disease (GVHD) by day 100 post-transplantation and chronic GVHD at 1 year post-transplantation.
* Evaluate the risk of relapse at 1 year post-transplantation.
* Determine overall survival at 1 year post-transplantation.
OUTLINE:
* Nonmyeloablative preparative regimen: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine IV over 1 hour on days -6 to -2. Patients also undergo total-body irradiation on day -1. Some patients\* may also receive anti-thymocyte globulin (ATG) IV twice daily on days -6 to -4.
NOTE: \*Patients who have not had prior combination chemotherapy within the past 3 months OR who only received 1 prior induction course for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blast crisis receive ATG during the preparative regimen.
* Umbilical cord blood transplantation (UCBT): Patients undergo UCBT from an unrelated donor on day 0.
* Graft-versus-host disease prophylaxis: Patients receive cyclosporine IV over 2 hours or orally 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. Patients also receive mycophenolate mofetil IV or orally twice daily beginning on day -3 and continuing until day 30 or until 7 days after engraftment.
After transplantation, patients are followed periodically for 2 years.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Primary
* Determine the safety of nonmyeloablative preparative regimen comprising cyclophosphamide, fludarabine, and total-body irradiation with or without anti-thymocyte globulin, in terms of non-relapse mortality at day 100 post-transplantation, in patients with advanced hematologic malignancies, metastatic breast cancer, or renal cell cancer who are undergoing umbilical cord blood transplantation from an unrelated donor.
Secondary
* Determine the hematopoietic recovery and degree of chimerism on days 21, 60, 100, 180, and 360 post-transplantation.
* Determine the incidence of grade II-IV and III-IV acute graft-versus-host disease (GVHD) by day 100 post-transplantation and chronic GVHD at 1 year post-transplantation.
* Evaluate the risk of relapse at 1 year post-transplantation.
* Determine overall survival at 1 year post-transplantation.
OUTLINE:
* Nonmyeloablative preparative regimen: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine IV over 1 hour on days -6 to -2. Patients also undergo total-body irradiation on day -1. Some patients\* may also receive anti-thymocyte globulin (ATG) IV twice daily on days -6 to -4.
NOTE: \*Patients who have not had prior combination chemotherapy within the past 3 months OR who only received 1 prior induction course for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blast crisis receive ATG during the preparative regimen.
* Umbilical cord blood transplantation (UCBT): Patients undergo UCBT from an unrelated donor on day 0.
* Graft-versus-host disease prophylaxis: Patients receive cyclosporine IV over 2 hours or orally 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. Patients also receive mycophenolate mofetil IV or orally twice daily beginning on day -3 and continuing until day 30 or until 7 days after engraftment.
After transplantation, patients are followed periodically for 2 years.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Breast Cancer
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
stage IV breast cancer
recurrent renal cell cancer
stage III renal cell cancer
stage IV renal cell cancer
adult acute myeloid leukemia in remission
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
recurrent adult acute myeloid leukemia
recurrent childhood acute myeloid leukemia
accelerated phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
recurrent adult Hodgkin lymphoma
recurrent/refractory childhood Hodgkin lymphoma
stage III adult Hodgkin lymphoma
stage IV adult Hodgkin lymphoma
stage III chronic lymphocytic leukemia
stage IV chronic lymphocytic leukemia
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
refractory anemia
adult acute lymphoblastic leukemia in remission
blastic phase chronic myelogenous leukemia
childhood acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia in remission
childhood chronic myelogenous leukemia
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
noncontiguous stage II adult Burkitt lymphoma
noncontiguous stage II adult diffuse large cell lymphoma
noncontiguous stage II adult diffuse mixed cell lymphoma
noncontiguous stage II adult diffuse small cleaved cell lymphoma
noncontiguous stage II adult immunoblastic large cell lymphoma
noncontiguous stage II adult lymphoblastic lymphoma
noncontiguous stage II grade 1 follicular lymphoma
noncontiguous stage II grade 2 follicular lymphoma
noncontiguous stage II grade 3 follicular lymphoma
noncontiguous stage II mantle cell lymphoma
noncontiguous stage II marginal zone lymphoma
noncontiguous stage II small lymphocytic lymphoma
recurrent adult acute lymphoblastic leukemia
recurrent adult Burkitt lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent childhood acute lymphoblastic leukemia
recurrent childhood lymphoblastic lymphoma
recurrent childhood large cell lymphoma
recurrent childhood small noncleaved cell lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent mantle cell lymphoma
recurrent marginal zone lymphoma
recurrent small lymphocytic lymphoma
refractory chronic lymphocytic leukemia
refractory multiple myeloma
secondary acute myeloid leukemia
splenic marginal zone lymphoma
stage III adult Burkitt lymphoma
stage III adult diffuse large cell lymphoma
stage III adult diffuse mixed cell lymphoma
stage III adult diffuse small cleaved cell lymphoma
stage III adult immunoblastic large cell lymphoma
stage III adult lymphoblastic lymphoma
stage III grade 1 follicular lymphoma
stage III grade 2 follicular lymphoma
stage III grade 3 follicular lymphoma
stage III mantle cell lymphoma
stage III marginal zone lymphoma
stage III small lymphocytic lymphoma
stage IV adult Burkitt lymphoma
stage IV adult diffuse large cell lymphoma
stage IV adult diffuse mixed cell lymphoma
stage IV adult diffuse small cleaved cell lymphoma
stage IV adult immunoblastic large cell lymphoma
stage IV adult lymphoblastic lymphoma
stage IV grade 1 follicular lymphoma
stage IV grade 2 follicular lymphoma
stage IV grade 3 follicular lymphoma
stage IV mantle cell lymphoma
stage IV marginal zone lymphoma
stage IV small lymphocytic lymphoma
refractory anemia with excess blasts in transformation
refractory anemia with ringed sideroblasts
refractory cytopenia with multilineage dysplasia
refractory anemia with excess blasts
childhood myelodysplastic syndromes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anti-thymocyte globulin
Intervention Type
DRUG
cyclophosphamide
Intervention Type
DRUG
cyclosporine
Intervention Type
DRUG
fludarabine phosphate
Intervention Type
DRUG
mycophenolate mofetil
Intervention Type
DRUG
radiation therapy
Intervention Type
PROCEDURE
umbilical cord blood transplantation
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
DISEASE CHARACTERISTICS:
* Diagnosis of 1 of the following:
* Acute myeloid leukemia (AML), meeting 1 of the following criteria:
* In first complete remission (CR1) by morphology AND at high risk, as evidenced by 1 of the following:
* AML secondary to myelodysplastic syndromes (MDS)
* High-risk cytogenetics, such as those associated with MDS or complex karyotype
* More than 2 courses of therap were required to obtain a CR
* In second or greater CR by morphology
* In morphologic relapse or persistent disease, defined as \> 5% blasts in normocellular bone marrow OR any percentage of blasts if blasts have unique morphologic markers (e.g., auer rods)
* In cytogenetic relapse (without morphologic relapse)
* Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:
* In CR1 by morphology AND at high risk, as evidenced by 1 of the following:
* High-risk cytogenetics, such as t(9;22), t(1;19), t(4;11), or other MLL rearrangements
* More than 1 course of therapy was required to obtain a CR
* In second or greater CR by morphology
* In morphologic relapse or persistent disease as defined for AML
* In cytogenetic relapse (without morphologic relapse)
* Chronic myelogenous leukemia
* All types allowed except refractory blast crisis
* Non-Hodgkin's lymphoma (NHL)
* No intermediate- or high-grade NHL or mantle cell NHL that is progressive on salvage therapy
* Stable disease allowed provided it is non-bulky
* Hodgkin's lymphoma
* No progressive disease on salvage therapy
* Stable disease allowed provided it is non-bulky
* Chronic lymphocytic leukemia
* Multiple myeloma
* MDS
* Any subtype allowed, including refractory anemia if there is severe pancytopenia or complex cytogenetics
* Less than 5% blasts
* If patient has blasts ≥ 5% then they must undergo induction therapy before transplantation
* Metastatic breast cancer
* Disease must have responded to recent chemotherapy OR in plateau after response to chemotherapy
* Renal cell cancer
* Acquired bone marrow failure syndromes
* Small percentage of blasts that is equivocal between marrow regeneration vs early relapse allowed provided there are no associated cytogenetic markers consistent with relapse (for patients with AML or ALL)
* Must have a 4/6 HLA-A, -B, and -DRB1 matched unrelated umbilical cord blood donor available
* No 5/6 or 6/6 HLA-A , -B, and -DRB1 matched sibling donor available
* No more than 2 antigen mismatches at the HLA-A, -B, or -DRB1 loci NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
* Karnofsky performance status 60-100% OR Lansky performance status 50-100% (pediatric patients)
* Albumin \> 2.5 g/dL
* Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance \> 40 mL/min (pediatric patients)
* Adults with creatinine \> 1.2 mg/dL or a history of renal dysfunction must have a creatinine clearance \> 40 mL/min
* Transaminases \< 5 times upper limit of normal (ULN)
* Bilirubin \< 3 times ULN
* LVEF ≥ 35%
* DLCO \> 30% of predicted
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No evidence of HIV infection or known HIV-positivity
* No decompensated congestive heart failure
* No uncontrolled cardiac arrhythmia
* No requirement for supplemental oxygen
* No active, serious infection
* Recent mold infection (e.g., Aspergillus) allowed provided patient has received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by an infectious disease specialist
PRIOR CONCURRENT THERAPY:
* No prior irradiation that precludes the safe administration of 1 additional dose of 200 cGy of total-body irradiation
* At least 3 months since prior myeloablative bone marrow transplantation
* Diagnosis of 1 of the following:
* Acute myeloid leukemia (AML), meeting 1 of the following criteria:
* In first complete remission (CR1) by morphology AND at high risk, as evidenced by 1 of the following:
* AML secondary to myelodysplastic syndromes (MDS)
* High-risk cytogenetics, such as those associated with MDS or complex karyotype
* More than 2 courses of therap were required to obtain a CR
* In second or greater CR by morphology
* In morphologic relapse or persistent disease, defined as \> 5% blasts in normocellular bone marrow OR any percentage of blasts if blasts have unique morphologic markers (e.g., auer rods)
* In cytogenetic relapse (without morphologic relapse)
* Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:
* In CR1 by morphology AND at high risk, as evidenced by 1 of the following:
* High-risk cytogenetics, such as t(9;22), t(1;19), t(4;11), or other MLL rearrangements
* More than 1 course of therapy was required to obtain a CR
* In second or greater CR by morphology
* In morphologic relapse or persistent disease as defined for AML
* In cytogenetic relapse (without morphologic relapse)
* Chronic myelogenous leukemia
* All types allowed except refractory blast crisis
* Non-Hodgkin's lymphoma (NHL)
* No intermediate- or high-grade NHL or mantle cell NHL that is progressive on salvage therapy
* Stable disease allowed provided it is non-bulky
* Hodgkin's lymphoma
* No progressive disease on salvage therapy
* Stable disease allowed provided it is non-bulky
* Chronic lymphocytic leukemia
* Multiple myeloma
* MDS
* Any subtype allowed, including refractory anemia if there is severe pancytopenia or complex cytogenetics
* Less than 5% blasts
* If patient has blasts ≥ 5% then they must undergo induction therapy before transplantation
* Metastatic breast cancer
* Disease must have responded to recent chemotherapy OR in plateau after response to chemotherapy
* Renal cell cancer
* Acquired bone marrow failure syndromes
* Small percentage of blasts that is equivocal between marrow regeneration vs early relapse allowed provided there are no associated cytogenetic markers consistent with relapse (for patients with AML or ALL)
* Must have a 4/6 HLA-A, -B, and -DRB1 matched unrelated umbilical cord blood donor available
* No 5/6 or 6/6 HLA-A , -B, and -DRB1 matched sibling donor available
* No more than 2 antigen mismatches at the HLA-A, -B, or -DRB1 loci NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
* Karnofsky performance status 60-100% OR Lansky performance status 50-100% (pediatric patients)
* Albumin \> 2.5 g/dL
* Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance \> 40 mL/min (pediatric patients)
* Adults with creatinine \> 1.2 mg/dL or a history of renal dysfunction must have a creatinine clearance \> 40 mL/min
* Transaminases \< 5 times upper limit of normal (ULN)
* Bilirubin \< 3 times ULN
* LVEF ≥ 35%
* DLCO \> 30% of predicted
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No evidence of HIV infection or known HIV-positivity
* No decompensated congestive heart failure
* No uncontrolled cardiac arrhythmia
* No requirement for supplemental oxygen
* No active, serious infection
* Recent mold infection (e.g., Aspergillus) allowed provided patient has received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by an infectious disease specialist
PRIOR CONCURRENT THERAPY:
* No prior irradiation that precludes the safe administration of 1 additional dose of 200 cGy of total-body irradiation
* At least 3 months since prior myeloablative bone marrow transplantation
Maximum Eligible Age
69 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Masonic Cancer Center, University of Minnesota
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudio G. Brunstein, MD, PhD
Role: STUDY_CHAIR
Masonic Cancer Center, University of Minnesota
References
Explore related publications, articles, or registry entries linked to this study.
Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant. 2012 Jun;18(6):963-8. doi: 10.1016/j.bbmt.2012.02.012. Epub 2012 Mar 16.
Reference Type
DERIVED
Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011 May 12;117(19):5261-3. doi: 10.1182/blood-2011-01-329573. Epub 2011 Mar 14.
Reference Type
DERIVED
Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Mar 26;113(13):2902-5. doi: 10.1182/blood-2008-10-184093. Epub 2009 Jan 28.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT2000-15
Identifier Type: OTHER
Identifier Source: secondary_id
2000LS039
Identifier Type: -
Identifier Source: org_study_id